Published in Liver Transpl on January 01, 2002
Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl (2002) 1.41
Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis (2009) 0.95
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res (2012) 0.86
A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86
Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol (2004) 0.81
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol (2012) 0.77
IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens. Int J Organ Transplant Med (2010) 0.76
Liver transplantation for hepatitis C virus related liver disease. Postgrad Med J (2005) 0.76
Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients. Dis Markers (2014) 0.75
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants. World J Gastroenterol (2012) 0.75
Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci Rep (2017) 0.75
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl (2006) 2.02
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology (2004) 1.92
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl (2005) 1.79
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology (2006) 1.63
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl (2007) 1.46
Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology (2011) 1.44
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest (2008) 1.32
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol (2002) 1.32
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology (2007) 1.27
Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood (2008) 1.27
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl (2004) 1.22
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci (2002) 1.20
Minimizing morbidity of organ donation: analysis of factors for perioperative complications after living-donor nephrectomy in the United States. Transplantation (2008) 1.20
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem (2001) 1.18
Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol (2002) 1.17
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res (2008) 1.16
Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling. Hepatology (2009) 1.16
Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes (2003) 1.15
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. Am J Surg Pathol (2006) 1.12
The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl (2002) 1.11
Spontaneous rupture of a silicone peritoneal dialysis catheter presenting outflow failure and peritonitis. Perit Dial Int (2011) 1.10
NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol (2010) 1.09
Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells. Transplantation (2012) 1.09
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl (2003) 1.08
Dental health status of liver transplant candidates. Liver Transpl (2007) 1.05
Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol (2005) 1.05
Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol (2010) 1.04
Hepatic resection in 170 patients using saline-cooled radiofrequency coagulation. HPB (Oxford) (2005) 1.04
Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. Hepatology (2007) 1.03
Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology (2003) 1.03
Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl (2005) 1.02
Langerhans cells are not required for graft-versus-host disease. Blood (2010) 1.01
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest (2005) 1.00
Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation (2002) 0.99
Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology (2013) 0.99
Themes of liver transplantation. Hepatology (2010) 0.98
Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation (2004) 0.97
Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl (2003) 0.97
Influence of cold ischemia time and graft transport distance on postoperative outcome in human liver transplantation. Surg Today (2002) 0.95
Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation. Transplantation (2007) 0.95
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
Pediatric liver transplantation. A single center experience spanning 20 years. Transplantation (2002) 0.95
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
Caroli's disease and orthotopic liver transplantation. Liver Transpl (2006) 0.92
The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood (2013) 0.92
Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys (2011) 0.92
Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology (2011) 0.91
Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg (2005) 0.91
Memory T cells migrate to and reject vascularized cardiac allografts independent of the chemokine receptor CXCR3. Transplantation (2011) 0.91
Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation (2004) 0.91
Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol (2012) 0.90
An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology (2005) 0.90
Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl (2011) 0.90
Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol (2004) 0.90
Cotransplanted hepatic stellate cells enhance vascularization of islet allografts. Microsurgery (2007) 0.89
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Intrahepatic biliary anatomy of living adult liver donors: correlation of mangafodipir trisodium-enhanced MR cholangiography and intraoperative cholangiography. AJR Am J Roentgenol (2002) 0.89
Roles of dendritic cells in murine hepatic warm and liver transplantation-induced cold ischemia/reperfusion injury. Hepatology (2013) 0.89
Webcasting pathology department conferences in a geographically distributed medical center. Hum Pathol (2004) 0.89
Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation (2005) 0.89